Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:IMR) ) has issued an update.
Imricor Medical Systems, Inc. has initiated the VISABL-VT clinical trial following the successful first-in-human ventricular ablation guided by real-time interventional cardiac magnetic resonance (iCMR) at Amsterdam University Medical Centre. This groundbreaking procedure, marking several world firsts, represents a significant milestone for Imricor and the field of electrophysiology, potentially enhancing the company’s market position and offering improved treatment options for patients with irregular heartbeats.
More about Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
Imricor Medical Systems, Inc. is a leader in developing MRI-compatible products for cardiac catheter ablation procedures. The company’s primary product, the Vision-MR Ablation Catheter, is designed for real-time MRI guidance, offering potentially higher success rates and safer treatments compared to traditional x-ray guided methods. Imricor’s products are approved in the EU, Saudi Arabia, and New Zealand, with plans to expand into the U.S. and other Middle Eastern markets. The company collaborates with major MRI equipment vendors to establish Interventional Cardiac Magnetic Resonance Imaging (iCMR) labs.
YTD Price Performance: -13.24%
Average Trading Volume: 326,496
See more data about IMR stock on TipRanks’ Stock Analysis page.